Top Markets
Coin of the day
Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX
Rang in Aktien #4247
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Aktienkurs
$34.24
Marktkapitalisierung
$3.99B
Veränderung (1 Tag)
0.21%
Veränderung (1 Jahr)
31.49%
Land
US
Handel Viking Therapeutics, Inc. (VKTX)

Kategorie

Kursverlauf für Viking Therapeutics, Inc. (VKTX)
Höchster Schlusskurs: $33.94 am 2026-08-01

Niedrigster Schlusskurs: $8.59 am 2015-04-01
Kursverlauf der Aktie von Viking Therapeutics, Inc. von 2015 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -9.08%
2025 -20.83%
2024 152.59%
2023 215.71%
2022 16.84%
2021 -21.08%
2020 -20.48%
2019 -10.51%
2018 130.53%
2017 246.93%
2016 -60.36%
2015 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$549.63 41.96%
US
$1.05K 48.56%
NL
$121.62 -12.98%
AU
$146.79 493.55%
US
$764.47 6.25%
CH